Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells
Open Access
Abstract
Niclosamide is used to treat intestinal parasite infections, as being an anthelmintic drug. Recently, several papers suggest the niclosamide inhibits multiple signaling pathways, which are highly activated and mutated in cancer. Here, niclosamide was evaluated for identifying strategies to overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance. Although niclosamide (100–200 nM) alone did not bring about cell death, combinations of niclosamide and TRAIL led to apoptotic cell death in carcinoma cells, but not in normal cells. Niclosamide markedly increased DR5 protein levels, including cell-surface DR5, and decreased c-FLIP protein levels. Down-regulation of DR5 by specific small interfering RNA (siRNA) and ectopic expression of c-FLIP markedly blocked niclosamide plus TRAIL-induced apoptosis. Our findings provide that niclosamide could overcome resistance to TRAIL through up-regulating DR5 on the cell surface and down-regulating c-FLIP in cancer cells. Taken together, niclosamide may be an attractive candidate to overcome TRAIL resistance.Keywords
Funding Information
- This work was supported by an NRF grant funded by the Korea Government (MSIP) (2014R1A5A2010008 and NRF-2016R1A2B2013393)
- This work was supported by a 2018 Scholar Research Grant from Keimyung University (.)
This publication has 29 references indexed in Scilit:
- Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctionsSpringerPlus, 2016
- Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 familyInternational Journal of Molecular Medicine, 2016
- Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancerGynecologic Oncology, 2014
- Effect of Niclosamide on Basal-like Breast CancersMolecular Cancer Therapeutics, 2014
- Anticancer Effects of Niclosamide in Human GlioblastomaClinical Cancer Research, 2013
- Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosisCell Death & Differentiation, 2004
- TRAIL and apoptosis induction by TNF-family death receptorsOncogene, 2003
- Apo2L/TRAIL and its death and decoy receptorsCell Death & Differentiation, 2003
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- The TRAIL to selective tumor deathNature Medicine, 1999